Arrowhead Pharmaceuticals Inc (ARWR)

Arrowhead Pharmaceuticals Inc is trading at $59.90, down 0.98% on the session. The 50 day average sits at $69.79 and the 200 day at $71.73, which puts the stock in a downtrend. RSI is at 40.9, which reads as weak, and MACD is bullish crossover. Volume is below average.

The nearest support is around $56.56 with resistance near $60.46, so that band frames the current range. Average daily movement is roughly $2.51, or about 4.2% of the share price, which is what any stop placement has to allow for. The overall health score of 32 out of 100 combines a trend score of 0, momentum of 50 and a risk score of 58.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.